XNW5004

Phase 2Small molecule

EEvopoint Biosciences Inc.

XNW5004 is one of 71 small molecule programs targeting Advanced Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Prostate CancerNot yet recruiting

LymphomaNot yet recruiting

Prostate CancerRecruiting

Advanced Prostate CancerPhase 2

Not yet recruiting

LymphomaPhase 2

Not yet recruiting

Prostate CancerPhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

Cabenuva

GSK

Preclinical

1 4

XNW5004

EEvopoint Biosciences Inc.

Phase 2

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Lymphoma

NCT06702605

Q4 2028

Phase 2Not yet recruiting

Advanced Prostate Cancer

NCT07730580

Clinical

Trials by Indication[1]

Relapsed/Refractory1 trial

To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors

Completed·EEvopoint Biosciences Inc.·Phase 1/2·NCT06558513·120 enrolled

Lymphoma1 trial

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Not yet recruiting·EEvopoint Biosciences Inc.·Phase 2·NCT06702605·50 enrolled

Prostate Cancer1 trial

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

Recruiting·EEvopoint Biosciences Inc.·Phase 1/2·NCT06702995·307 enrolled

Advanced Prostate Cancer1 trial

An Open-Label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of XNW5004 Tablets in Combination With Anti-Tumor Therapy in Participants With Advanced Prostate Cancer

Not yet recruiting·EEvopoint Biosciences Inc.·Phase 2·NCT07730580·242 enrolled

Squamous Cell Carcinoma of Head and Neck1 trial

A Phase Ib/II Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Terminated·EEvopoint Biosciences Inc.·Preclinical·NCT06022757·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for XNW5004. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XNW5004 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XNW5004. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Evopoint Biosciences Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEvopoint Biosciences Inc.

XNW5004

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2028

Trials by Indication[1]

Relapsed/Refractory1 trial

Lymphoma1 trial

Prostate Cancer1 trial

Advanced Prostate Cancer1 trial

Squamous Cell Carcinoma of Head and Neck1 trial

References

Drug Info

Quick Facts

Related News